CAR T-Cell Therapy Enables Durable Remission in Adolescent with Relapsed Lymphoma: A Singapore Case Study
核心洞察
A 16-year-old Singaporean boy diagnosed with lymphoma (搜索) in October 2021 relapsed after six cycles of chemotherapy in June 2022.
CAR T-cell therapy, an experimental immunotherapy typically reserved for adults, was approved by the hospital ethics board and administered in October 2022.
The therapy, which has a 30% success rate in adults with relapsed lymphoma (搜索), produced a dramatic response with only mild side effects, enabling the patient to return to school within six months.
A teenage patient in Singapore has achieved a remarkable recovery from relapsed lymphoma (搜索) following CAR T-cell therapy, an experimental immunotherapy rarely used in pediatric populations. The case, managed by a medical team at the National University Hospital (NUH), underscores both the potential of cell-based gene therapies in adolescent blood cancers and the critical role of charitable funding in enabling access to cutting-edge treatments.
Muhammad Danish Muhammad Irfan was 16 years old when a prolonged cough escalated into a medical emergency in October 2021. He became breathless and was admitted to the intensive care unit at NUH, where physicians ultimately diagnosed him with lymphoma (搜索) — a type of blood cancer that originates in the lymphatic system and affects infection-fighting white blood cells.
Lymphoma (搜索) is uncommon among children below 18 years old, with approximately five new cases per year in Singapore, according to Allen Yeoh, head of division and senior consultant from the division of paediatric haematology and oncology in the Department of Paediatrics at the Khoo Teck Puat – National University Children's Medical Institute (搜索) within NUH.
Chemotherapy and Relapse
Around March 2022, Danish began chemotherapy, which consisted of six cycles administered during hospital stays of at least two weeks, every three weeks. Despite the intensive regimen, his disease proved refractory. In June 2022, Danish relapsed, setting the stage for a more aggressive therapeutic approach.
CAR T-Cell Therapy: An Experimental Option for a Pediatric Patient
Faced with relapsed disease, the clinical team turned to CAR T-cell therapy, an immunotherapy in which a patient's own T cells are genetically engineered to recognize and attack cancer cells. The treatment was funded by the Children's Cancer Foundation (搜索), a philanthropic organization that supports pediatric patients and their families.
However, the therapy presented a regulatory and clinical challenge: CAR T-cell therapy is typically administered only in adults. Yeoh noted that his team had to seek permission from the hospital's ethics board before proceeding. In adults with relapsed lymphoma (搜索), the therapy carries a success rate of approximately 30 percent.
The procedure was performed in October 2022. Danish responded to the therapy with only mild side effects, and his physicians monitored him closely throughout the process. The clinical outcome was striking: the treatment "made such a difference that Danish was able to return to school about six months later."
Long-Term Management and Functional Recovery
Following CAR T-cell therapy, Danish continues to visit the hospital monthly for infusions to manage immunodeficiency, a recognized side effect of the treatment. Despite this ongoing medical requirement, his functional recovery has been substantial. Driven by a desire to catch up after putting his information technology studies at Ngee Ann Polytechnic on hold for approximately one and a half years, Danish took on extra modules and graduated in 2025 — half a year earlier than expected. He has received offers in computing courses from four local universities and will join Singapore Management University in August.
Caregiver Resilience and Support Systems
The case also highlights the extraordinary demands placed on caregivers during pediatric cancer treatment. Danish's father, Muhammad Irfan Mohamed Awi, 53, a single father of three, served as the sole designated visitor during periods of social distancing restrictions. For approximately two months, his days revolved entirely around his son's needs. He slept on a sofa bed in his son's hospital room, prepared freshly made meals daily due to Danish's immunocompromised state, and managed household responsibilities between hospital visits.
"It was not easy. I cried when he was sleeping in the ward so he wouldn't know. I kept telling myself that there is somebody out there who is worse off than me," Irfan said. "To all fathers out there who are having challenges, it is important to have a support system. You cannot do it alone."
The successful application of CAR T-cell therapy in this adolescent patient, made possible through institutional ethics approval and charitable funding, represents a noteworthy example of expanding access to advanced immunotherapies beyond adult populations in carefully selected pediatric cases.